Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer

Onkologie

Volumn 35, Issue 1-2, 2012, Pages 8-9

  Kaira, Kyoichi ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL EFFECTIVENESS; DISEASE CONTROL; DRUG EFFICACY; EDITORIAL; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUINAZOLINES;

EID: 84856822096     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000336306     Document Type: Editorial

References (9)

1. Saito H, Murakami S, Kondo T, Oshita F, Noda K, Yamada K: Effectiveness of erlotinib in advanced non-small-cell lung cancers in cases of gefitinib resistance after treatment of more than 6 months. Onkologie 2012;35: DOI: 10.1159/000335736.
2. Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo, Yamamoto N: Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010;68:99-104.
3. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Chi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33. (Pubitemid 47041225)
4. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
5. Asami K, Kawahara M, Atagi S, Kawaguchi T, Okishio K: Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 2011;73:211-6.
6. Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T: Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer 2011;74:268-73.
7. Wong MK, Lo AI, Lam B, Lam WK, IP MS, Ho JC: Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2010;65:1023-8.
8. Song ZB, Yu YF, Chen ZW, Lu S: Erlotinib as a salvage treatment for patients with advanced nonsmall cell lung cancer after failure of gefitinib treatment. Chin Med J 2011;24:2279-83.
9. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-60.